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Background: Hospital workers have been the most frequently and severely affected professional group during the COVID-19
pandemic, and have a big impact on transmission. In this context, innovative tools are required to measure the symptoms compatible
with COVID-19, the spread of infection, and testing capabilities within hospitals in real time.
Objective: We aimed to develop and test an effective and user-friendly tool to identify and track symptoms compatible with
COVID-19 in hospital workers.
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Methods: We developed and pilot tested Hospital Epidemics Tracker (HEpiTracker), a newly designed app to track the spread
of COVID-19 among hospital workers. Hospital staff in 9 hospital centers across 5 Spanish regions (Andalusia, Balearics,
Catalonia, Galicia, and Madrid) were invited to download the app on their phones and to register their daily body temperature,
COVID-19–compatible symptoms, and general health score, as well as any polymerase chain reaction and serological test results.
Results: A total of 477 hospital staff participated in the study between April 8 and June 2, 2020. Of note, both health-related
(n=329) and non–health-related (n=148) professionals participated in the study; over two-thirds of participants (68.8%) were
health workers (43.4% physicians and 25.4% nurses), while the proportion of non–health-related workers by center ranged from
40% to 85%. Most participants were female (n=323, 67.5%), with a mean age of 45.4 years (SD 10.6). Regarding smoking habits,
13.0% and 34.2% of participants were current or former smokers, respectively. The daily reporting of symptoms was highly
variable across participating hospitals; although we observed a decline in adherence after an initial participation peak in some
hospitals, other sites were characterized by low participation rates throughout the study period.
Conclusions: HEpiTracker is an already available tool to monitor COVID-19 and other infectious diseases in hospital workers.
This tool has already been tested in real conditions. HEpiTracker is available in Spanish, Portuguese, and English. It has the
potential to become a customized asset to be used in future COVID-19 pandemic waves and other environments.
Trial Registration: ClinicalTrials.gov NCT04326400; https://clinicaltrials.gov/ct2/show/NCT04326400
(JMIR Public Health Surveill 2020;6(3):e21653) doi: 10.2196/21653
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Introduction
The rapid spread of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus responsible for
COVID-19, requires an urgent, collaborative, and
multidisciplinary response supported by innovative methods
[1]. Hospital staff (including both health-related and
non–health-related professionals) form the backbone of the
response to the ongoing pandemic. However, these professionals
are among the most frequently and severely affected by
COVID-19 [2,3]. Indeed, the disease has had a tremendous
impact on the hospital workforce of affected areas due to the
high risk of infection and heavy workloads. The dissemination
of SARS-CoV-2 within hospitals may result in large nosocomial
outbreaks and other devastating consequences. In the current
scenario, timely information on how these risks evolve and are
managed is almost anecdotal and reliable scientific data are
urgently needed. In addition, understanding the determinants
of SARS-CoV-2 infection and transmission by individuals with
asymptomatic or very mild symptomatic cases of COVID-19
is crucial for the design of containment strategies.
In August 2020, the World Health Organization (WHO) declared
that the COVID-19 pandemic is far from controlled. The
cumulative number of confirmed COVID-19 cases across 216
countries, areas, or territories worldwide amounts to over
21,989,366, and 775,893 confirmed deaths have been reported
to date [4]. Record daily numbers of both infections and deaths
are seen in many countries, with many of them already
experiencing “second waves” after lockdowns were lifted [5].
Spain is among the countries hardest hit by the pandemic, with
over 376,000 total cases and over 28,000 deaths as of August
2020 [6].
COVID-19–related symptoms are nonspecific, resembling
common cold symptoms in immunocompetent individuals.
According to the Centers for Disease Control and Prevention
(CDC) [7], the list of common COVID-19 symptoms includes
fever, cough, and shortness of breath that may appear 2 to 14
days after exposure to SARS-CoV-2; other nonrespiratory
symptoms are also frequent [8]. Whenever these symptoms
appear with epidemiological evidence (ie, after close contact
with an infected subject or after visiting an area with ongoing
community spread), further clinical assessment is needed.
The real-time assessment of COVID-19–related symptoms,
their spread, and testing capabilities in hospital settings requires
the use of innovative tools. In this context, digital health
technologies have great potential to improve surveillance and
epidemic control, primarily through increased information
coverage, faster acquisition and distribution of information,
rapid case tracking, and improved proximity tracing [9-11].
Consequently, smartphone- and web-based health apps aimed
at tracking COVID-19 are on the rise. Although digital tools
can promote public health, they can be intrusive, erode
individual freedoms, or leave vulnerable populations behind
[12].
Here, we summarize the development of Hospital Epidemics
Tracker (HEpiTracker) [13], a newly designed app to track
COVID-19 and other epidemics in hospitals. We also describe
the pilot study performed across different areas and phases of
the outbreak. The goal of the app is to help already overwhelmed
hospital staff to actively monitor and assess COVID-19
infections and compatible symptoms in a population of hospital
workers. We provide the basic data of the app and descriptive
statistics of the pilot study, which illustrate the applicability of
HEpiTracker in practical settings.
Methods
Overview
On March 14, 2020, a multidisciplinary group of individuals
with varied backgrounds held the first of many daily meetings
to discuss, by means of a “think tank” approach, research
avenues aimed at mitigating the impact of the COVID-19 crisis.
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As part of the Active Monitoring And Determinants of Incident
Infection of COVID-19 in a Hospital population (AMADIICH)
initiative, this multidisciplinary group created a framework
designed to collect large amounts of heterogeneous data
regarding COVID-19 in hospital staff, from shoe-leather
epidemiology to big data and biosensors [14-16]. One of the
main priorities of the group was speed, and the tools were
designed with the aim of being applied during the first wave of
COVID-19, and any subsequent outbreaks. Ethics approval of
the AMADIICH research protocol was granted by the University
Hospital of la Princesa’s ethics board on March 19, 2020
(Proceedings of the Standing Commission CEIm 02/20, registry
number 4061). The study was registered on ClinicalTrials.gov
with the identifier NCT04326400. Individual informed consent
was a requirement of participation and was obtained on the first
screen of the HEpiTracker app, with tick boxes to give or deny
consent.
The standard process of reporting COVID-19–related symptoms
differs by area and center, but typically starts with a phone call
from the employee to the occupational health unit (OHU) of
the center. The employee is then advised to self-isolate at home,
where he/she receives a polymerase chain reaction (PCR) test.
If the test is positive, he/she remains in home isolation. If the
test is negative but there are symptoms, the employee remains
in isolation and the test is repeated during the following days.
Therefore, workers can only return to work once they do not
have symptoms and have returned two consecutive negative
PCR tests. The OHU should always have access to the status
of all employees and is typically responsible for escalating the
data. The purpose of the HEpiTracker app is to provide an easier,
homogenous, and transparent way of tracking positive PCR
results and symptoms. The tracking happens automatically and
relieves the health manager from manually updating the
aggregated information and calculating statistics. It can also
provide the updated information to the workers themselves in
a transparent manner.
We provide descriptive data obtained in the pilot study that
illustrate the applicability of the app in practical settings. We
would like to clarify that we do not intend to study the factors
behind app adoption or the effect these types of tools have on
infection rates. These, and other related issues, are beyond the
scope of this article. What we do present is a working app that
can help already overwhelmed hospital staff to actively monitor
and assess COVID-19 infections and compatible symptoms in
the hospital worker population.
App Development Process
As mentioned above, a mobile app to help monitor the spread
of COVID-19 within hospitals was conceived after a state of
emergency and full lockdown were declared in Spain on March
14, 2020. Following initial discussions and ethical approval, a
stepwise approach was carried out by ASELCIS software
developers [17] to create the first version of the new app within
a week and then to enhance its functionalities regularly. After
several iterations, a minimum set of variables to include in the
HEpiTracker App were identified, including demographic and
occupational data, symptoms, previous comorbidities, and lab
testing variables (Table 1).
There was a feedback process from users within our scientific
committee, which includes doctors, nurses, computer science
specialists, mathematicians, physicists, and statisticians, but not
patients themselves, although during the development of the
app several authors became infected or were quarantined due
to COVID-19. The app also included a self-assessment of overall
health status based on an ordinal Likert scale from 0 to 10.
HEpiTracker was made available for both Android and iOS
operating systems at Google and Apple stores, respectively.
Once HEpiTracker was up and running, we designed a pilot
study in real-world conditions to test the feasibility of the app.
Specifically, we tested the app in several hospitals across regions
with different incidence rates and undergoing different phases
of the COVID-19 pandemic: Hospital Can Misses (Eivissa)
from April 9, 2020; Hospital Lucus Augusti (Lugo) from April
10, 2020; Hospital Álvaro Cunqueiro (Vigo) from April 10,
2020; Hospital Institut Català d'Oncologia (ICO; l’Hospitalet,
Badalona, Girona, Tarragona-Terres de l’Ebre) from April 8,
2020; Hospital de Alta Resolución Loja (Granada) from April
13, 2020; and Hospital Universitario de La Princesa (Madrid)
from April 9, 2020.
Hospital staff in 5 Spanish autonomous communities (Andalusia,
Balearics, Catalonia, Galicia, and Madrid) were invited to
download the app on their smartphones [13], and to register
their daily body temperature, COVID-19–compatible symptoms,
and general health score, as well as any PCR or serological test
results. All staff in the participating hospitals, namely doctors,
nurses, technicians, administrative workers, wardens, cleaners,
managers, cafeteria staff, security, and other occupations were
invited to participate, with no exclusion criteria.
In addition to answering Yes/No for the presence of daily
symptoms, participants self-assessed their overall health by
means of a visual analog scale (VAS), and they disclosed
whether they had a history (either of diagnosis or treatment) of
rhinitis, allergy, or chronic obstructive pulmonary disease
(COPD)/chronic bronchitis, as well as their smoking status.
Further, participants manually entered their body temperature
in degrees Celsius to one decimal. They were also invited to
register the outcome and the date of any COVID-19 laboratory
test (PCR, IgG, or IgM); these could have been performed
routinely at their center, throughout the study by risk exposure,
or as a result of the presence of symptoms or suspicion of having
the disease (Figure 1).
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Table 1. Variables included in the HEpiTracker App.
ValuesType and variable
Demographic data









Degrees Celsius, reported to one decimalBody temperature
Yes/NoCough
Yes/NoShortness of breath
Yes/NoOdynophagia or pain when swallowing
Yes/NoMalaise
Yes/NoAlterations of sense of smell




Yes/NoChronic bronchitis or chronic obstructive pulmonary disease
Never/former/currentSmoker
Lab testing
Positive or negativeCOVID-19 testd
aDNI: Documento nacional de identidad; NIE: Número de identificación de extranjero.
b“Other” category without text/alphanumericals.
cDepartments/services include the following: Pathology, Cardiology, General and Digestive System Surgery, Oral and Maxillofacial Surgery, Plastic
and Reconstructive Surgery, Medical-Surgical Dermatology and Venereology, Gastroenterology - Digestive System, Gynecology and Obstetrics, General
Medicine, Nuclear Medicine, Preventive Medicine, Neurophysiology, Neurology, Ophthalmology, Medical Oncology, Radiation Oncology,
Otorhinolaryngology, Pediatrics and Specific Areas Children's Health, Radiodiagnosis - Diagnostic Imaging, Traumatology and Orthopedic Surgery,
Urology, Emergencies, restricted-COVID-19 area, quarantine area, isolation area.
dInformation recorded includes the date and type of test: polymerase chain reaction, IgG, or IgM.
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Figure 1. HEpiTracker graphical display and screens.
Participant Withdrawal Criteria
A participant could withdraw from the study at any time (by
simply not filling in their own information or by removing the
app from their smartphone). However, given the ongoing public
health emergency during this COVID-19 outbreak, it was agreed
that any data already obtained would be kept for analysis and
grouped tabulation. In addition, participants would be withdrawn
at the discretion of the investigators if they failed to comply
with the protocol procedures (eg, dummy data, relative of
hospital staff, and other).
Data Life Cycle
The first data entry was made by a user of the mobile app. The
coding language is based on Ionic, which allows developers to
create native apps with web coding such as HTML, CSS, and
JavaScript. Users’ initial data and subsequent symptom records
are automatically transferred to an Odoo V11 Enterprise Edition
server application [18]. The coding language is Python 3 on the
back-end and JavaScript on the front-end. This first data transfer
is carried out in encrypted form with an SSL certificate and a
HTTPS protocol. In this server application, the data is processed
and sent to the PostgreSQL database via an SSL certificate.
Final Data Storage
The storage of data is done in a PostgreSQL database in an
encrypted way. In addition, user data is stored anonymously
with an internal code assigned to each participant. In this way,
the user's identification number is related to the internal code,
and all data entered is linked to it, preventing the end user
(principal investigator) from having access to the user's personal
data.
Backups
To guarantee the storage of data and avoid its loss or
modification, a backup is made daily that is kept in three data
centers (DCs) on three different continents, thus ensuring the
integrity of the data in the event of any serious problem or
inconvenience in any of the three DCs.
All individual participants’ collected data were stored on secure
ASELCIS servers. Data were anonymized with a unique
identifier by user and hospital. Statistics were performed by
ISGlobal and IdIsBa with databases already anonymized over
a PostgreSQL connection under a user and password
requirement.
Statistical Analysis
Study reports were sent to the participating hospitals. These
reports included descriptive information regarding changes in
the symptoms and incidence of COVID-19 infection by age
group, sex, job category, and department/section. We followed
the STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) guidelines for reporting observational
studies [19]. Continuous variables were expressed as mean and
standard deviation, and categorical variables were expressed as
number and percentage.
Results
A total of 477 hospital staff participated in the study between
April 8 and June 2, 2020 (Table 2).
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Of note, both health-related (n=329) and non–health-related
(n=148) professionals participated in the study. Overall
participation by center was low; the highest participation rate
of potential participants was 5.06% at Hospital Álvaro
Cunqueiro (128 of 2529 potential participants), followed by a
participation rate of 2.97% at ICO L'Hospitalet (20 of 674
potential participants). Most participants were female (67.7%),
with a mean age of 45.4 years (SD 10.6). Regarding smoking
habits, 13.0% and 34.2% of participants were current or former
smokers, respectively (Table 2). Over two-thirds of participants
(68.8%) were health workers (43.4% physicians and 25.4%
nurses); however, the proportion of non–health workers by
center ranged from 40% to 85%, and the distribution of job
category by center was also highly variable. Participation was
therefore lower for non–health workers, although we did obtain
valuable data about them. Regarding comorbidities, participants
reported being previously diagnosed with or currently in
treatment for the following respiratory conditions: allergic
rhinitis (25.4%), asthma (13.8%), and chronic bronchitis/COPD
(1.0%).
The daily report of symptoms was highly variable across
participants; overall, 2% to 6% of the source population in each
hospital engaged with the app. Although we observed a decline
in adherence after an initial participation peak in some hospitals,
other sites were characterized by poor participation rates since
inception and throughout the study period (Figure 2).
There were no major differences across hospitals in the
distribution of respiratory comorbidities (asthma, rhinitis, and
chronic bronchitis/COPD), smoking status, or symptoms, namely
cough, shortness of breath, malaise, or anosmia (Table 3).
However, for temperature and overall health status scored from
0 to 10, there were subtle but not clinically significant
differences. Finally, the percentage of positive PCR tests was
highly variable, from 39% of participants at La Princesa (16/41
participants), to 20% at ICO Girona (2/10), 9.5% (16/169) at
Álvaro Cunqueiro, 8.8% (6/68) at ICO L’Hospitalet, and 3.6%
(4/116) at Lucus Augusti.
A daily summary display of these results was made available
for circulation at all participating sites each morning during the
study period (Figure 3).
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Table 2. Demographic and clinical characteristics of 477 HEpiTracker users.
ValueCharacteristics
323 (67.7)Female, n (%)
45.4 (10.6)Age (years), mean (SD)
Hospital, n (%)
11 (2.3)Hospital Can Misses (Eivissa)
112 (23.5)Hospital Lucus Augusti (Lugo)
169 (35.4)Hospital Álvaro Cunqueiro (Vigo)




2 (0.4)Tarragona-Terres de l’Ebre
20 (4.2)Hospital de Alta Resolución de Loja (Granada)
48 (8.6)Hospital Universitario de La Princesa (Madrid)
24 (5.0)Other











Respiratory conditions, n (%)
121 (25.4)Allergic rhinitis
66 (13.8)Asthma
5 (1.0)Chronic bronchitis or chronic obstructive pulmonary disease
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Figure 2. Distribution of HEpiTracker coverage in each hospital by calendar day (April 8 to May 30, 2020) as of June 2, 2020. ICO: Institut Català
d'Oncologia.
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Figure 3. HEpiTracker results by hospital and by calendar day.
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6 (25.0)10 (8.93)4 (9.76)0 (0.00)7 (10.3)2 (20.0)2 (10.0)3 (27.3)29 (17.2)3 (15.0)Asthma
8 (33.3)23 (20.5)11 (26.8)1 (50.0)12 (17.6)1 (10.0)3 (15.0)6 (54.5)52 (30.8)4 (20.0)Rhinitis
0 (0.00)1 (0.89)0 (0.00)0 (0.00)0 (0.00)1 (10.0)0 (0.00)0 (0.00)3 (1.78)0 (0.00)Chronic bronchi-
tis or COPDb
Smoking, n (%)
9 (37.5)38 (33.9)11 (26.8)0 (0.0)25 (36.8)4 (40.0)7 (35.0)2 (18.2)61 (36.1)6 (30.0)Former
9 (37.)56 (50.0)28 (68.3)2 (100)36 (52.9)6 (60.0)12 (60.0)9 (81.8)87 (51.5)7 (35.0)Never
6 (25.0)18 (16.1)2 (4.88)0 (0.00)7 (10.3)0 (0.0)1 (5.00)0 (0.00)21 (12.4)7 (35.0)Current
Symptoms, n (%)
4 (16.7)3 (2.68)4 (9.76)0 (0.00)6 (8.82)1 (10.0)2 (10.0)0 (0.00)14 (8.28)0 (0.00)Cough
2 (8.33)0 (0.00)2 (4.88)0 (0.00)3 (4.41)0 (0.0)1 (5.00)0 (0.00)2 (1.18)0 (0.00)Shortness of
breath
1 (4.17)0 (0.00)3 (7.32)0 (0.00)3 (4.41)0 (0.0)0 (0.00)1 (9.09)2 (1.18)0 (0.00)Malaise













































aICO: Institut Català d'Oncologia. 
bCOPD: chronic obstructive pulmonary disease.
Discussion
Summary of Results
HEpiTracker is a newly designed mobile app aimed at
monitoring the spread of COVID-19 symptoms and testing
among professionals in hospital settings. Although the first
wave of the pandemic in Spain and other countries is thought
to be over, many experts warn that lockdown lifts might be
premature [20]. In the current situation, the use of novel tools
to measure and track the effects of the pandemic in real time
may help tackle the forthcoming waves of the pandemic [4,6].
We tested the HEpiTracker app in a sample of 477 hospital staff
including both health-related and non–health-related
professionals from 9 centers in 5 regions of Spain experiencing
different stages of the COVID-19 pandemic. The daily report
of COVID-19–related symptoms was highly variable across
participating hospitals, as well as the reported infection testing
rates. We observed a decline in adherence after an initial
participation peak in some hospitals, while other sites were
characterized by low participation rates throughout the study
period. It is worth noting that our pilot study aimed to test the
technical aspects of the app in different real-world hospital
settings, all in different stages of the COVID-19 pandemic, but
not its deployment or coverage. In general, an acceptable
response rate for any epidemiological study is 80% or higher
for usability [21,22]. Having said that, the total workforce in
our 9 participating hospitals ranges from around 150 to over
3000 workers, which fluctuate seasonally and yearly. As
reported, the overall response rate varied from 2% to 6% of the
source population in each hospital in this study.
In future analyses, techniques and tools used in artificial
intelligence and machine learning will be explored. For instance,
machine learning can be used to forecast new cases or to identify
relevant phenotypes [20].
Discussion of Results and Work in the Field
Mobile apps are effective, valid tools for monitoring very
diverse patterns in real-life conditions [23]. However, a key
issue in mobile app–based monitoring involves increasing
adherence and reinforcement for changing established behaviors.
Our participation data show that adherence to the app should
be improved, perhaps by providing some real-time feedback,
composed of aggregated data from a given user’s hospital and
overall estimates, to the users. In response to the ongoing
COVID-19 pandemic, several apps and digital health solutions
have already been developed [24-26], as digital technology has
the potential to improve surveillance and epidemic control. This
is achieved primarily through increased information coverage,
faster acquisition and distribution of information, rapid case
tracking, and improved proximity tracing. In this context, some
have already identified new opportunities to reshape current
health care systems, including the widespread adoption of
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electronic health records and the development of better mobile
health apps and other disruptive technologies [10]. Indeed,
digital health solutions are a promising asset to improve the
quality of health care at a more sustainable cost. In a recent
review, the uptake of and engagement with health and
well-being smartphone apps was associated with capability,
opportunity, and motivation [27].
It should be stressed that the present study did not intend to
study the factors that determine app adoption or the impact of
the app on infection rates. These, along with other relevant
issues, are outside the scope of this paper and would only be
addressed by a larger-scale study that would be complex in its
design and execution. However, this pilot study allowed us to
identify some strengths and limitations of the app that will be
addressed in the following sections.
Strengths and Potential of the Platform
Some strengths of HEpiTracker include novelty, flexibility, and
the ability to quickly modify it and include new updates and
information. Notably, the app is now available in several
languages (Spanish, English, and Portuguese) and is accepted
by both health care professionals and non–health care
professionals in hospital settings. In the near future, we plan to
design customized versions to be used in primary care, by
security forces, and even in universities once in-class teaching
is resumed.
Limitations
However, our results must be interpreted in light of the following
limitations. Despite fulfilling all European Union regulations
and disclaimers on data protection, concerns with data privacy
were raised by legal departments or individual managers in
several nonparticipating hospitals, so clarity among leadership
should be ensured. When evaluating usability and user
experience of mobile health (mHealth) solutions, there are
standardized questionnaires such as The Standardized User
Experience Percentile Rank Questionnaire (SUPR-Qm) [28]
for user experience and the mHealth App Usability
Questionnaire (MAUQ) [29], which can aid the evaluation of
apps; these can be used to prospectively assess HEpiTracker.
However, the main limitation of the study was adherence to the
app. In particular, we found it difficult to maintain participant
engagement for weeks, especially when the local COVID-19
situation deescalated by the end of April/May 2020.
Unfortunately, the inclusion of alarm reminders for the daily
recording of symptoms and temperature was not effective.
Indeed, a proper communication and marketing strategy for
wider implementation will be critical for its future use. We have
already developed QR codes and templates of posters to pin in
hospital entrances, elevators, and notice boards, which serve as
a way to download HEpiTracker directly on any platform.
This lack of adherence, however inspired the next evolution of
the app, consisting of an activity wristband that will incorporate
HEpiTracker plus a number of other utilities. This evolution of
HEpiTracker, named Epiwrist (an “epidemiologist on your
wrist”), could passively monitor all HEpiTracker variables, as
well as others. Epiwrist would include a gyroscope to assess
hand-washing behavior (duration and frequency), synchronized
with a cough sensor to identify if the cough is directed to your
sleeve (good) or your hand (bad), and a continuous heart rate
monitor, oxygen saturation meter, and built-in thermometer. It
is envisaged that Epiwrist will also measure physical activity,
sleep duration and patterns, blood pressure, and respiratory rate.
The development of this software and hardware started in May
2020; it was designed by engineers at Softlution [30]. Although
the development of Epiwrist is envisaged and a first prototype
has been manufactured in China, it will require time and effort
to perform real-life testing and obtain approvals.
During the COVID-19 epidemic, OHUs in hospitals were in
charge of diagnosing health care workers with symptoms of the
disease, and applying and changing protocols from their
respective public health institutions, which included the study
of contacts within the hospital, affecting both hospitalized
patients and staff. OHUs also reported the cases to the local
epidemiological surveillance systems. Moreover, OHUs
participated in the constant updating and implementation of
internal protocols for COVID-19 prevention in collaboration
with the preventive medicine units. In our study, some hospitals
showed an unwillingness to participate because they believed
that HEpiTracker would interfere with established tracking of
health care providers and surveillance. Moreover, they claimed
that it could affect the privacy rights of participants. In general,
public health interventions during infectious outbreaks can be
divided into those consisting of personal actions (eg, physical
distancing, personal hygiene, and use of protective equipment),
case and contact identification (eg, test-trace-track-isolate,
reactive school or workplace closure), regulatory actions (eg,
governmental limits on sizes of gatherings or business capacity;
stay-at-home orders; proactive school, workplace, and public
transport closure or restriction; cordon sanitaire or internal
border closures), and international border measures (eg, border
closure or enforced quarantine).
Conclusions
A key priority during the ongoing COVID-19 pandemic is to
identify the combination of measures that minimizes societal
and economic disruption while adequately controlling infection
[31]. Our aim with HEpiTracker was therefore focused on case
and contact identification, namely test-trace-track-isolate within
hospital staff, as they were becoming infected with COVID-19
disproportionately more frequently and severely than the general
population. The significance and impact of mobile apps,
including HEpiTracker, in helping to tackle COVID-19 should
be assessed further with more research conducted by other
groups in real conditions. As we are facing a new virus and
disease [32], future directions and scenarios should be further
assessed [33].
HEpiTracker is an already available tool to monitor COVID-19
and other epidemics in hospital workers. It has been tested in
real conditions and might represent a stepping stone toward
effective health policies in response to future waves of the
pandemic. HEpiTracker is available in Spanish, Portuguese,
and English and holds the potential to become a customized
asset to be used in future COVID-19 pandemic waves and other
environments.
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